Disease/Infection News

RSS

Scientists reveal the mechanism of liquid-liquid phase separation of SARS-CoV-2 nucleocapsid

A team of scientists from the United States has recently revealed how interactions between the SARS-CoV-2 nucleocapsid protein and the double-stranded RNA motifs impart distinct droplet properties that can support multiple viral functions. The study is currently available on the bioRxiv* preprint server.

16 Jun 2021

Reducing coronavirus-related mortality through senolytics

A study recently published in the journal Science explores the concept of senescent cells (SnC) having a hyperinflammatory response and the use of a class of small molecules called senolytics to combat this.

16 Jun 2021

Could daily rapid testing replace mandatory quarantine to prevent imported SARS-CoV-2 infections?

A new study, released as a preprint on the medRxiv* server, examines the relative effectiveness of varying strategies, such as pre-flight testing, longer or shorter periods of quarantine, tests for release, or daily testing after the flight, using modeling tools. The results show that it is feasible to avoid quarantine by the use of lateral flow testing daily for five days, achieving higher reductions in the number of secondary cases caused by an infected traveler in the country of destination.

16 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

A new paper in the journal Nature offers a reassuring answer, showing that convalescent COVID-19 patients, some of whom had received vaccination as well, retain antiviral antibodies and neutralizing activity, as well as memory B cells, for up to 6-12 months from infection.

16 Jun 2021

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

A new approach focusing on cellular repair may be an effective strategy to address the pandemic.

16 Jun 2021

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

A new approach focusing on cellular repair may be an effective strategy to address the pandemic.

16 Jun 2021

Novavax COVID vaccine co-administered with flu vaccine appears safe and effective

Researchers from the UK recently reported the results of a sub-study that evaluates the safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine when co-administered with an approved seasonal influenza vaccine.

16 Jun 2021

Increased viral replication and shedding in nonhuman primates carrying SARS-CoV-2 B.1.1.7 variant

A team of researchers from the US and UK used the AGM intranasal model of SARS-CoV-2 infection to determine differences between a contemporary SARS-CoV-2 D614G variant circulating in summer 2020 and the B.1.1.7 UK variant of concern that emerged in late 2020.

16 Jun 2021

Cissampelos pareira (velvetleaf) exhibits anti-SARS-CoV-2 potential

Cissampelos pareira (Cipa), also known as velvetleaf, is a widely used hormone modulator used to treat reproductive disorders and fever. Research has shown that it can inhibit three serotypes of Dengue virus (DENV) and affect various hormones.

16 Jun 2021

Prior vaccination against diphtheria and tetanus associated with less severe COVID-19

The researchers found that individuals with registered diphtheria or tetanus vaccinations were less likely to develop severe COVID-19 than people who had only received other vaccinations. The results of this study are posted to the medRxiv* preprint server.

16 Jun 2021

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

Rapidly evolving SARS-Cov-2 strains may give rise to escape variants

The number of COVID-19 variants is growing rapidly, so much that the scale and scope of mutation may pose a threat to the continuing successful use of the current vaccines and therapies.

16 Jun 2021

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research. There were no adverse effects.

16 Jun 2021

Studies shed new light on disease processes in tuberculosis

Two new studies have cast unprecedented light on disease processes in tuberculosis, identifying key genetic changes that cause damage in the lungs and a drug treatment that could speed up recovery.

16 Jun 2021

COVID-19 Vaccine DSMB can serve as model for future situations

Clinical evaluation of three COVID-19 vaccine candidates in 2020-21 during a worldwide pandemic that killed or sickened millions was unprecedented in terms of urgency and scope.

16 Jun 2021

Chronic fatigue a significant challenge for most long COVID patients

Researchers in Canada have conducted a study suggesting that the majority of patients living with long COVID (coronavirus disease) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience chronic fatigue that is at least as severe as that seen in several other clinical conditions.

15 Jun 2021

Neanderthal-derived genetic locus influences COVID-19 severity in humans

Researchers in the United States and Estonia have identified four genetic variants on a chromosome 3 haplotype that may be responsible for driving the association between this locus and the severity of coronavirus disease 2019 (COVID-19).

15 Jun 2021

ACT Accelerator partnership welcomes commitment of 870 million vaccine doses, highlights funding gaps

At the close of this year’s G7 Leaders’ summit, the Prime Minister of the United Kingdom of Great Britain and Northern Ireland announced a donation of an additional 870 million vaccine doses from attendees, with the majority to be delivered through COVAX, the vaccines pillar of the Access to COVID 19 Tools Accelerator, within the next year.

15 Jun 2021

Global leaders pledge to share COVID-19 vaccine doses internationally at the G7 summit

In a landmark agreement at the G7 summit, held in Cornwall, the United Kingdom of Great Britain and Northern Ireland, global leaders have pledged to share COVID-19 vaccine doses internationally, in support of global equitable access and to help end the acute phase of the pandemic.

15 Jun 2021

Disease/Infection News

Scientists reveal the mechanism of liquid-liquid phase separation of SARS-CoV-2 nucleocapsid

Reducing coronavirus-related mortality through senolytics

Could daily rapid testing replace mandatory quarantine to prevent imported SARS-CoV-2 infections?

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

Novavax COVID vaccine co-administered with flu vaccine appears safe and effective

Increased viral replication and shedding in nonhuman primates carrying SARS-CoV-2 B.1.1.7 variant

Cissampelos pareira (velvetleaf) exhibits anti-SARS-CoV-2 potential

Prior vaccination against diphtheria and tetanus associated with less severe COVID-19

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

Rapidly evolving SARS-Cov-2 strains may give rise to escape variants

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

Studies shed new light on disease processes in tuberculosis

COVID-19 Vaccine DSMB can serve as model for future situations

Chronic fatigue a significant challenge for most long COVID patients

Neanderthal-derived genetic locus influences COVID-19 severity in humans

ACT Accelerator partnership welcomes commitment of 870 million vaccine doses, highlights funding gaps

Global leaders pledge to share COVID-19 vaccine doses internationally at the G7 summit

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News